Two-year point estimates of various outcomes by calendar year of HCT. Shown for all patients (A), age <18 years (B), and all patients who underwent transplantation for NMD (C). ∗Relapse in patients who underwent transplantation for malignancy; aGVHD, acute GVHD; cGVHD-All, cGVHD whether treated with systemic IS (cGVHD-IS) or not; NRM∗, NRM in all patients.